欧盟批准Tezspire用于对标准治疗不反应的重鼻膜聚虫。 The EU approved Tezspire for severe nasal polyps unresponsive to standard treatment.

欧洲委员会已经批准了AstraZeneca的Tezspire, 与Amgen共同开发, 治疗患有慢性犀牛皮炎的成年人, The European Commission has approved AstraZeneca’s Tezspire, developed with Amgen, for treating adults with chronic rhinosinusitis with nasal polyps who don’t respond to standard therapies. 该药物靶向胸腺基质淋巴细胞生成素，与鼻用皮质类固醇一起使用，并在试验中显示可以降低息肉的严重程度、充血和手术需求，同时降低类固醇的使用。 The drug, which targets thymic stromal lymphopoietin, is used with nasal corticosteroids and has shown in trials to reduce polyp severity, congestion, and surgery needs while lowering steroid use. 已在美国批准用于成人和12岁及以上儿童, 已有超过10万名患者使用该药物治疗严重喘. Approved in the U.S. for adults and children 12 and older, it’s already used by over 100,000 patients for severe asthma. 批准为患有不受控制的症状的病人提供了一个新的选择,一些国家正在进行监管审查。 The approval offers a new option for patients with uncontrolled symptoms, with regulatory reviews ongoing in several countries.